Agenus has experienced a recent recovery, but cash burn and a weak balance sheet pose substantial risks. Find out why I'm ...

Clinical-stage immuno-oncology company Agenus (NASDAQ:AGEN) recently executed a 1-for-20 reverse stock split to give the ...

Agenus (AGEN) shares rallied 6.8% in the last trading session to close at $5.31. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session.

So, even if BOT + BAL fail to reach these early revenue range estimates, the stock still appears undervalued at present. In ...

At close: April 26 at 4:00 PM EDT ...

Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results ...